- an observation that has been confirmed repeatedly and is accepted as true (although its truth is never final)
- The book is full of far-flung theories without any basis in scientific fact.
- In particular, that Communication underlines the fact that the information generated by the veterinary monitoring, surveillance and control activities and programmes provides crucial scientific evidence for the Community institutions and governments to support decision on disease prevention and control measures.
- EFSA also refers to the fact that its Scientific Panel on Biological Hazards agreed with the view of the Scientific Committee for Food (SCF) that 50-100 mg added nitrite per kg of meat products may suffice for many products and in other products, especially those with a low salt content and having a prolonged shelf life, addition of between 50-150 mg/kg nitrite is necessary to inhibit growth of C. botulinum.
- The Commission takes note, moreover, of the fact that IFP disseminates the results of this work using a number of tools, such as its own scientific journal Oil & Gas Science and Technology, which is freely accessible online, the organisation of and participation in conferences, the publication of works, partnerships with other research centres and doctoral sponsorships.
- Given the fact that the submission of new scientific evidence constitutes a cumulative condition for the fulfillment of the requirements of Article 95(5) EC Treaty, their absence has as consequence the rejection of the notification without the need to further examine the fulfillment of other conditions.
- The fact that the manufacturer and his suppliers should not have ‘used any ingredients that have been tested on animals by others for the purpose of developing new cosmetic products’ means that the manufacturer and his suppliers should not have used ingredients for which data resulting from animal tests made by others for the purpose of developing a new cosmetic product are available for instance in scientific literature.
- Despite the fact that there is an indication that Guidant would likely have been one of the key players in the market for DES, acting as a major competitive constraint vis-à-vis the two current competitors J & J and Boston Scientific, the evidence collected in the investigation also proved that the other new entrants will be likely to exert sufficient competitive constraints on the market for DES, compensating for the loss of competition resulting from J & J’s acquisition of Guidant (Medtronic, Abbott, Conor/Biotronik and Sorin).